Download this Application Note to Learn More
T cell therapies offer hugely exciting potential in immunotherapy, but manufacturing hurdles must be overcome in order to reach this potential. Chimeric antigen receptor (CAR) T cell therapy in particular faces daunting challenges throughout each stage of isolation, activation, genetic modification, and expansion. These include compromised cell quality and inconsistency, as well as the need to meet stringent regulatory requirements and minimize the risk of contamination. Reliable and scalable clinical-grade cell culture media provide the vital foundation to address these limitations.
This application note evaluates the efficacy of Gibco™ CTS™ OpTmizer™ One SFM (serum-free medium) in improving the production quality of CRISPR-Cas9–transfected CAR T cells.
The results of the study indicate that CTS OpTmizer One SFM supports T cell expansion, viability, and gene editing efficiency. CTS OpTmizer One SFM also maintained higher percentages of memory T cells, enhanced CD8⁺ T cell populations, and increased antitumor activity compared to another serum‑free medium. The results of this study demonstrate that CTS OpTmizer One SFM is a robust solution for enhancing the manufacturability of GMP-grade cell therapies.
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific
